Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda F Baker

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|September 3, 2020
Antisense Inhibition of Prekallikrein to Control Hereditary AngioedemaDanny M Cohn, Nicholas J Viney, Lauré M Fijen, et al.
European Heart Journal|April 18, 2012
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trialMaartje E Visser, Gilbert Wagener, Brenda F Baker, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2016
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersStanley T Crooke, Brenda F Baker, T Jesse Kwoh, et al.
The New England Journal of Medicine|July 30, 2015
Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaDaniel Gaudet, Veronica J Alexander, Brenda F Baker, et al.
Journal of the Peripheral Nervous System : JPNS|November 8, 2022
Liver-directed drugs for transthyretin-mediated amyloidosisThomas H Brannagan, John L Berk, Julian D Gillmore, et al.
Nucleic Acid Therapeutics|March 1, 2019
IONIS-PKK<sub>Rx</sub> a Novel Antisense Inhibitor of Prekallikrein and Bradykinin ProductionJason D Ferrone, Gourab Bhattacharjee, Alexey S Revenko, et al.
ESC Heart Failure|December 7, 2020
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 dataNicholas J Viney, Shuling Guo, Li-Jung Tai, et al.
The New England Journal of Medicine|March 16, 2022
Inhibition of Prekallikrein for Hereditary AngioedemaLauré M Fijen, Marc A Riedl, Laura Bordone, et al.
The New England Journal of Medicine|May 25, 2017
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense OligonucleotidesMark J Graham, Richard G Lee, Teresa A Brandt, et al.
Muscle & Nerve|July 13, 2020
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosisP James B Dyck, Teresa Coelho, Marcia Waddington Cruz, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|September 3, 2020
Antisense Inhibition of Prekallikrein to Control Hereditary AngioedemaDanny M Cohn, Nicholas J Viney, Lauré M Fijen, et al.
European Heart Journal|April 18, 2012
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trialMaartje E Visser, Gilbert Wagener, Brenda F Baker, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2016
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersStanley T Crooke, Brenda F Baker, T Jesse Kwoh, et al.
The New England Journal of Medicine|July 30, 2015
Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaDaniel Gaudet, Veronica J Alexander, Brenda F Baker, et al.
Journal of the Peripheral Nervous System : JPNS|November 8, 2022
Liver-directed drugs for transthyretin-mediated amyloidosisThomas H Brannagan, John L Berk, Julian D Gillmore, et al.
Nucleic Acid Therapeutics|March 1, 2019
IONIS-PKK<sub>Rx</sub> a Novel Antisense Inhibitor of Prekallikrein and Bradykinin ProductionJason D Ferrone, Gourab Bhattacharjee, Alexey S Revenko, et al.
ESC Heart Failure|December 7, 2020
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 dataNicholas J Viney, Shuling Guo, Li-Jung Tai, et al.
The New England Journal of Medicine|March 16, 2022
Inhibition of Prekallikrein for Hereditary AngioedemaLauré M Fijen, Marc A Riedl, Laura Bordone, et al.
The New England Journal of Medicine|May 25, 2017
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense OligonucleotidesMark J Graham, Richard G Lee, Teresa A Brandt, et al.
Muscle & Nerve|July 13, 2020
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosisP James B Dyck, Teresa Coelho, Marcia Waddington Cruz, et al.
Pageof 6